Objective and Design. Individuals seeking treatment for chronic pain in multidisciplinary pain management services are typically already on high doses of pain medications. This cross-sectional cohort study of patients with long-term chronic pain examined profiles of polypharmacy and pain medication-related harm exposure.
Introduction
Chronic pain is a significant burden in Australia, as it is around the world, with an estimated cost of $34 billion annually to the individual, family, workplace, and compensation schemes [1] . Individuals who seek treatment in a multidisciplinary pain management service have usually already had pain for many years, have significant painrelated disability, and are already on high doses of pain medications, particularly opioids [2] . Controversy around the role of opioids in chronic pain management attracts a great level of debate as it places such patients at greater risk of various adverse outcomes, including gastrointestinal symptoms of nausea, vomiting, and constipation [3] ; dependency and dosage tolerance [4] ; endocrine disorders [5] ; opioid-induced hyperalgesia [6] ; and overdose or death [7, 8] . Indeed, in the United States, the number of deaths from oxycodone and other pharmaceutical opioids outnumbers the number of overdose deaths from illicit heroin and cocaine combined [9] . Combined drug therapy, with administration of multiple drug classes, may improve pain management when more than one physiological mechanism or system is implicated [10] . However, the resultant polypharmacy increases the potential for adverse interactions and side effects. Further, the overall profile of polypharmacy is often overlooked and oversimplified in clinical studies, which tend to only record the total number of medications or number of classes of medications being taken [11] . We propose that this is too simplistic for studies of chronic pain. Not all pain medications are "equal" in potential harms, and the majority of complexities relating to polypharmacy are not currently captured using such simple descriptive measures. Ultimately, polypharmacy poses a significant clinical challenge, with potential for increased adverse effects [12] .
Harden et al. [13] developed and validated the Medication Quantification Scale III (MQS-III), which is a tool that quantifies the cumulative detriment of specific medications used in the treatment of chronic pain. Detriment here is defined as "the potential to produce acute or chronic adverse effects in patients with chronic non-malignant pain" (p. 365). It therefore captures the potential for processes such as toxicity, dysfunction, drug-drug interactions, addiction potential, abuse potential, insomnia, and tolerance. The tool has the advantage of quantifying the source of medication-related detriment, cumulative detriments within classes of medications (e.g., simple analgesics), as well as the total potential detriment. Higher levels of medication detriment have previously been found to correlate with pain intensity, pain-related disability and mood disturbance [2, 14] , and reduced quality of life [15] .
In this study, we sought to characterize the profile of potential medication-related harms and to evaluate the predominant sources of those harms, in a cohort of patients with chronic long-term pain attending a multidisciplinary pain management service. Further, we examined how traditional measurements of polypharmacy, such as the number of medications, map onto this more comprehensive measurement of potential medication-related harms.
Methods

Participants
Two hundred and twenty-four patients (116 male; 51.8%) participated. These patients had commenced treatment at the Caulfield Hospital Pain Management and Research Centre (CPMRC) and were aged 19 to 90 years (mean [M] = 51.69, standard deviation [SD] = 14.83), with 5% over 65 years of age. Only patients attending the clinic who had consented to participate and were taking medications for their pain during the study period were included in analyses. Nineteen additional patients had been excluded from analyses because they were not taking medications.
CPMRC is a subacute ambulatory care service that provides multidisciplinary treatment of patients with chronic pain and comprises medical staff (e.g., pain specialists, pain fellows, anesthetists, rehabilitation consultants, general practitioners) and senior allied health and nursing staff (e.g., physiotherapists, occupational therapists, psychologists, clinical and research nurses, social workers). Completion of a screening questionnaire battery is a requirement of entry to the service for triaging purposes. Patients then initially attend a medical appointment, after which they may follow various treatment pathways. For example, patients may only attend medical appointments, medical and allied health individual appointments, or medical and group therapy programs (e.g., multidisciplinary cognitive behavioral therapy or physiotherapy and occupational therapy group programs).
Materials and Procedure
The study was approved by the Alfred Hospital Human Research Ethics Committee. Patients attending CPMRC completed a standard battery of screening measures on admission to the service and provided informed consent. The International Association for the Study of Pain (IASP) Classifications for Chronic Pain were used to categorize the pain regions, systems, temporal characteristics, intensity, and etiology of each participant's pain [16] .
The dosage and frequency of all medications taken for pain, or that may have an impact on pain even if they were not prescribed specifically for pain (e.g., selective serotonin reuptake inhibitors), at admission to the pain service were recorded. These data were recorded during the first appointment with a pain medicine specialist.
Potential medication-related harms were measured with the MQS-III (see Supporting Information Tables S1 and S2 for detriment weightings used in this study, which were based on those proposed by Harden et al. [13] ). MQS-III detriment scores are calculated by multiplying the detriment weight allocated to a specific medication (from 1.1 for topical analgesics to 3.9 for benzodiazepines) by the therapeutic dosage range (e.g., subtherapeutic/pro re nata = 1; lower 50% of dosage range = 2; upper 50% of dosage range = 3, and supertherapeutic dosage range = 4), which generates an estimated detriment for each medication being taken for pain. For example, a patient who is taking 10 mg oxycodone every 4 hours will attract the following calculation: 3.4 (detriment weight) × 3 (upper 50% therapeutic dosage) = 10.2. Detriment scores may then be summed to calculate the total potential detriment exposure. The detriment weights have been validated for the MQS-I [17] and MQS-III [13, 18] , and have been shown to have good inter-rater reliability when completed by medical specialists. Harden et al. [13] demonstrated that the MQS-III has adequate reliability (internal consistency) for the total medication detriment (Cronbach alpha = 0.84). In the present study, the total MQS detriment scores were calculated as well as detriment scores for four medication categories: simple analgesics (e.g., paracetamol, nonsteroidal anti-inflammatory drugs [NSAIDs]), adjunctive analgesics (e.g., duloxetine, gabapentin), benzodiazepines, and opioids.
Statistical Design and Analysis
Pearson correlation and multivariate analyses were used to examine the relationship between the number of medications and the detriment weighting by the MQS, with between-subject factors of sex and age. Cluster analyses were used to examine patterns of medication detriment scores across the four classes of medications. The category-specific MQS scores were converted to z-scores for all cluster analyses to generate zero means and unit standard deviations. Hierarchical analysis, based on Ward's clustering method, was used to identify the number clusters from the z-score values of the four medication detriment categories (i.e., simple analgesics, adjunctive analgesics, benzodiazepines, opioids). This method was chosen because it minimizes within-cluster variance and creates distinct cluster solutions [19] . The maximum percentage change in the agglomeration coefficient recorded between successive cluster profiles was used as a stopping rule to reveal the final cluster structure. K-means cluster analyses were then used to identify cluster membership and cluster scores according to the number of cluster solutions identified.
Results
Patient Profile
The average duration of pain was 10.33 years. According to the IASP pain duration coding, two patients had mild pain for more than 6 months, 113 had medium severity of pain (<1 month Table 1 . Pain was reported to be continuous and nearly continuous by the majority of patients (N = 193, 87%).
Medication Use and Polypharmacy
Sixty-six percent of patients were taking simple analgesics, 61% were taking adjunctive analgesics, 80% were taking opioids, and 30% were on benzodiazepines. This cohort reported concurrently taking between one and three simple analgesics (M = 1.34, SD = 0.50), one and four adjunctive analgesics (M = 1.42, SD = 0.63), one and three opioids (M = 1.36, SD = 0.54), and one and two benzodiazepines (M = 1.67, SD = 0.37; one patient who was taking four different benzodiazepines was excluded from these descriptives as an outlier).
There was a high degree of polypharmacy, with patients taking, on average, three medications for pain (M = 3.19; range of one to nine medications) from two to three medication categories (M = 2.37 categories, SD = 0.89 categories). Only 18% of patients were taking medications from one medication class only, with 37% taking medications from two classes of medications, 35% from three medication categories, and 10% taking medications from all four of the medication categories.
Medication Detriment
The MQS-III total detriment scores ranged from 2.3 to 78.60 (M = 21.59, SD = 12.30). As expected, the total MQS-III score was correlated with the total number of pain medications (r[224] = 0.87, P < 0.001). There was no correlation between age and number of pain medications (r[224] = −0.07, P = 0.30) or age and MQS score (r[224] = −0.10, P = 0.15). A multivariate analysis of variance showed that there were no sex differences in the total number of pain medications taken, or MQS score; F(2, 221) = 1.50, P = 0.22, Pillai's trace = 0.01. While 80% of patients were taking opioids, these medications only accounted for an average of 41% of the total MQS score. The remaining detriments were attributed to simple analgesics (M = 27%), adjunctive analgesics (M = 22%), and benzodiazepines (M = 10%). See Table 2 for a profile of medication use and relative detriments from each medication category.
Medication Detriment Profile in Multidisciplinary Pain Management Service
To examine the profile of medication use in the multidisciplinary pain management setting, cluster analyses were performed. When examining the maximum percentage change in the agglomeration coefficient, noticeable jumps in percentage increase were identified for three-cluster (7% to 26% difference) and five-cluster (17% to 36% difference) solutions. K-means cluster analyses were used to generate the three-( Figure 1 ) and five-( Figure 2 ) cluster solutions. The MQS detriments from each category of pain medication for each cluster solution are presented in Table 3 and Table 4 , respectively.
For the three-factor solution, all groups were characterized by "average" simple analgesic use. Group one had low detriment scores in each medication category (N = 113), group two were above average in detriment for adjunctive analgesics, opioids, and benzodiazepines (N = 20), and group three were above average in opioidrelated detriment, but average or below average in the other medications (N = 91).
When distributing the sample across the five-factor solution, very different profiles of medication detriment emerged. Group one was characterized by relatively high benzodiazepine-related detriment and above average 
Discussion
This study aimed to characterize polypharmacy in patients attending a multidisciplinary pain management service and to investigate whether the typical measurement of the number of pain medications is reflective of exposure to medication-related harms. Not surprisingly, the number of medications was correlated with higher potential medication-related harms when using the MQS-III. This cohort study shows that opioids are used by 80% of patients who are taking medications for their pain upon entry to multidisciplinary pain treatment, and as a single class of medications, opioids make up one of the greatest contributions to the total potential medication detriment to which patients are exposed. However, it should be noted that the majority of medication related-harm exposure came from medications other than opioids. Moreover, patients who are predominantly taking high dosages of Figure 2 Cluster profile of medication detriment for the five-cluster solution (mean z-scores). simple analgesics were found to be exposed to similar levels of harm to those who are predominantly taking high dosages of opioids. These findings raise a number of clinical issues. First, perhaps the MQS-III detriment weights are not reflective of current harm-related concerns in medical pain management. Moreover, certain medication combinations may warrant increased detriment weights. Second, harm exposure from pain medication is clearly complex and studies of chronic pain should be characterizing which medications are contributing to polypharmacy and their cumulative harm exposure. In particular, although detriment scores and the number of medications were correlated, harm exposure is clearly not equal across all medications. Third, the high degree of harm-exposure from simple analgesics is worrying, considering their use in the treatment of chronic pain is questionable (e.g., see recent discussion; O'Callaghan [20] ).
No relationship was found between MQS-III scores and age. This may simply indicate that the experience of chronic pain is characterized by similar, and not additive, levels of polypharmacy over the lifespan. Alternatively, however, we suggest that medication detriment calculations should not only take into account daily dosage, but these detriments, or therapeutic dosage range, should be scaled according to age. This is particularly pertinent considering older patients are at greater risk of drug-drug interactions [21] and increased health detriments from pain medication due to age-related comorbidities (e.g., respiratory or renal disease) and age-related changes in immunosuppression [22] .
Two key patterns of polypharmacy were identified in this sample. When distributed across three profiles, one group showed low levels of medication detriment, one group had high levels of medication detriment across all drug classes (except simple analgesics), and a final group was predominantly high in potential opioid-related harm. When we examined the five profiles of polypharmacy, more diverse patterns of polypharmacy-related detriment emerged that are probably more clinically representative of medication usage in this population, which is typically heterogeneous with respect to the mechanisms underlying their pain. Again, there was a small group who was characterized by high levels of potential harm in all categories, three groups who were predominantly above average in a single category of medication (i.e., simple analgesics, adjunctive analgesics, or opioids), and one group who were above average in opioid and benzodiazepine medications. In both of the high polypharmacy clusters, there were above average levels of potential benzodiazepine-related harms, indicating that these patients may be the most mood disturbed. Patients on long-term opioid therapy are particularly likely to be co-prescribed with benzodiazepines to manage comorbid anxiety, mood, sleep, or substance abuse disorders [23] . A crucial finding here was that, on average, those primarily high in simple analgesics and opioids had similar levels of total medication-related harm exposure.
While debate around harm from pain medication has predominantly focused on opioid-related detriment, it is important to see that within this Australian multidisciplinary pain management setting, the major contributions to potential harms came from medications other than opioids. In particular, high levels of harm were attributable to use of benzodiazepines and multiple concurrent simple analgesics. Although medication, no doubt, has a role in pain management, exposure to potential detriment from these medications (using the MQS-III) is already known to be associated with increased health care visits, hospitalizations, pain severity, interference with activity, pain beliefs, depression and reduced quality of life [2, 14, 15] , suggesting that aggressive pharmacological treatment does not always bring about a clinically meaningful improvement in general well-being. Two previous studies that used earlier versions of the MQS found that multidisciplinary pain management services brought about a significant reduction in medication detriment after 6 months [14] and 12 months [24] , compared with patients who receive no treatment. Evidently, the multidisciplinary approach to pain management, which is well accepted as the gold standard in chronic pain management, may improve well-being while concurrently reducing exposure to medication-related harm. To date, however, the predictive utility of the MQS-III with respect to treatment efficacy has not been examined. Moreover, further research is required to specifically examine the relationship between medication-related detriment, function and mood.
Although concern about potential harm from pain medication should be at the forefront of the prescribing clinician's mind, we acknowledge that many pain conditions involve disruption to more than one level of the nervous system, which is best treated with multiple medications using combination drug therapy [25] [26] [27] . For example, some medication combinations, such as NSAIDS plus opioids, may provide additive effects as they target complementary pathways, whereas other combinations may result in synergistic effects that enhance therapeutic efficacy [27] . Indeed, a recent Cochrane systematic review of combined pharmacotherapy for treatment of neuropathic pain concluded that two-drug combinations, such as treatment with gabapentin plus opioids, showed superior efficacy in reducing pain intensity [10] . Ultimately, however, even though tailored combination drug therapy can be therapeutically beneficial, the evidence from clinical studies is inconclusive and often contradictory [27] . Moreover, such treatment may not necessarily increase function or quality of life considering the increased risk of side effects and detriment (e.g., due to central nervous system depression; Chaparro et al. [10] ).
Conclusions
The MQS-III was found to be a valuable tool to characterize potential medication-related harms, as well as to profile the source of those potential harms, within a multidisciplinary pain management setting. We identified multiple patterns of potential medication-related harms, with medications other than opioids being major contributors to potential harms. While combination drug therapy may provide increased efficacy in medical pain management, this inevitably increases potential health detriment. Additionally, it is clear that opioids are only one part of the story when it comes to medicationrelated concerns in the medical management of chronic pain. Further studies are required to examine whether changes in medication detriment, using the MQS-III, are predictive of long-term treatment outcomes from pain management interventions.
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